阿柏西普治疗眼底血管性疾病的临床研究新进展

Recent advances in clinical research on aflibercept treating fundus vascular diseases

阿柏西普是人血管内皮生长因子(vascular endothelial growth factor,VEGF)受体1和受体2胞外区结合域与人免疫球蛋白Fc段重组形成的融合蛋白,是一种新的抗VEGF药物,通过与VEGF紧密结合,降低血管通透性,进一步抑制新生血管的生成。多项大型Ⅲ期临床试验已验证了阿柏西普治疗湿性老年性黄斑变性、静脉阻塞黄斑水肿、糖尿病黄斑水肿和其他血管性眼底病的疗效,结果显示玻璃体内注射阿柏西普能够提高患者视力并且减轻眼底病变程度,为眼科医师提供了一种新的药物选择。本综述就阿柏西普的药理学特点以及它在眼底血管性疾病中的应用、疗效和安全性等方面进行论述。

Aflibercept is a soluble fusion protein which combines ligand-binding el- ements taken from the extracellular components of vascular endothelial growth factor （VEGF） receptor-1 and receptor-2 fused to the Fc portion of IgG, and it is a novel anti- VEGF drug, which can reduce vascular permeability and inhibit neoangiogenesis by binding VEGF tightly. A large number of phase llI clinical trials have demonstrated the satisfactory outcomes of aflibercept in the management of neovascular age-related mac- ular degeneration, macular edema secondary to retinal vein occlusion or macular edema and other retinal vascular diseases. Moreover, intravitreal injection of aflibercept can im- prove the visual acuity and attenuate the fundus lesion, which provides a new drug op- tion for physicians. The review will summarize the chemical properties of aflibercept and its application, safety and efficacy of aflibercept for the treatment of retinal vascular diseases.